NCT01996046

FDG PET/CT in Breast Cancer Bone Mets

18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) for the Evaluation of Response to Therapy in Bone-dominant Metastatic Breast Cancer

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 75 (estimated)
• Sponsor: University of Pennsylvania · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate baseline uptake on a FDG PET/CT scan in patients with breast cancer that has spread to the bones. A repeat FDG PET/CT scan will be done 4 weeks after the start of new breast cancer hormone treatment and again at 12 weeks after treatment start. The baseline uptake and change in uptake after the repeat scans will be compared to clinical long term outcomes such as time to progression and overall survival. In addition the uptake will be compared to the incidence of skeletal related events that are common occurrences in patients with cancer that has spread to the bones.

Detailed description

This is an observational study as all patients will receive the same research diagnostic test, an FDG PET/CT study performed at 4 weeks after starting new hormone treatment.

Conditions

• Estrogen Receptor Positive Breast Cancer
• Bone Metastases

Interventions

Type	Name	Description
OTHER	FDG PET/CT scan	\[18F\] FDG PET/CT scan at 4 weeks after starting new hormonal therapy

Timeline

• Start date: 2013-09-01
• Primary completion: 2023-07-31
• Completion: 2026-07-31
• First posted: 2013-11-27
• Last updated: 2025-09-02

Locations

1 site across 1 country: United States